Ergoteles’s KALA BIO KALA Stock Holding History

Ergoteles’s Portfolio KALA Stock Details KALA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-88	Closed	-$66K	–	1760
2022 Q2	$66K	Buy	+88	New	+$138K	﹤0.01%	1550
2020 Q4	–	Sell	-6	Closed	-$109K	–	795
2020 Q3	$109K	Buy	+6	New	+$138K	0.01%	533

Other funds holding KALA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

BOTOTLSJU

Board of Trustees of The Leland Stanford Junior University Redwood City, California $533M AUM 65.58% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

VAFP

Vahanian & Associates Financial Planning Saratoga Springs, New York $25.3M AUM 39.42% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Ergoteles's KALA Position: Q3 2022 in Review

Ergoteles sold out of KALA BIO (KALA) in Q3 2022, closing a stake of 88 shares — an estimated $66K sold.

Ergoteles first reported a position in KALA in Q3 2020 and held it in 2 quarters. The position peaked at $109K in Q3 2020. 53 funds tracked by Wall St. Rank hold KALA as of Q3 2022.

Ergoteles reported no remaining KALA BIO position as of Q3 2022 after selling out during the quarter.
Ergoteles sold 88 KALA BIO shares in Q3 2022, an estimated $66K.
Ergoteles first reported a position in KALA BIO in Q3 2020 and held it in 2 quarters.
Ergoteles's KALA BIO position peaked at $109K in Q3 2020.
53 funds tracked by Wall St. Rank held KALA BIO as of Q3 2022.

Based on Ergoteles's 13F filing for Q3 2022, filed 14 Nov 2022.